BioChem Pharma Inc.
SoundView Financial analyst Reijer Lenstra initiated coverage of BioChem Pharma Inc. with a "buy" and a one year price target of $16. Stock of the Canadian company is underfollowed, but investors are likely to notice the results from pivotal AIDS trials and the NDA filing for AIDS in the second half of 1994, Lenstra said.